New drug combo aims to tackle Hard-to-Treat myeloma

NCT ID NCT07217119

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing a combination of two drugs, belantamab mafodotin and feladilimab, in 25 people with relapsed/refractory multiple myeloma who have already tried at least three other treatments. The main goal is to check the safety of the combination and find the best dose to use in future studies. Researchers will also look at how well the drugs shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin and feladilimab
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early, small trial (25 people) focused on safety and dosing, not on proving the combination works. Side effects, including eye problems and blood issues, are possible. Many early-stage cancer drug combinations do not advance to become standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site

Atlanta, Georgia, 30322, United States
GSK Investigational Site

Madison, Wisconsin, 53792, United States
GSK Investigational Site

Fitzroy, Victoria, 3065, Australia
GSK Investigational Site

Melbourne, Victoria, 3000, Australia
GSK Investigational Site

Vancouver, British Columbia, V5Z1M9, Canada
GSK Investigational Site

Toronto, Ontario, M5G2M9, Canada
GSK Investigational Site

Villejuif, 94805, France
GSK Investigational Site

Hamburg, 22083, Germany
GSK Investigational Site

Utrecht, 3584CX, Netherlands
GSK Investigational Site

Pamplona Navarra, 31008, Spain
GSK Investigational Site

Stockholm, SE-141 86, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.